XILIO THERAPEUTICS INC. - COMMON STOCK

Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

22 سبتمبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

15 سبتمبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

06 سبتمبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results

09 أغسطس 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President

16 يونيو 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference

18 مايو 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer

17 مايو 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results

12 مايو 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

07 أبريل 2022 06:30:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

01 مارس 2022 06:30:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference

28 فبراير 2022 06:30:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day

03 فبراير 2022 06:30:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors

20 يناير 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors

06 يناير 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results

02 ديسمبر 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting

12 نوفمبر 2021 07:00:03 بحسب Nasdaq GlobeNewswire

Xilio Therapeutics Announces Closing of Initial Public Offering

26 أكتوبر 2021 16:05:00 بحسب Nasdaq GlobeNewswire